Health Technology · Pharmaceuticals: Major · NSE: ALEMBICLTD · data 2026-10-09
Alembic Limited
Health check: Strong (7.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹99.25
Market cap
₹2,563 cr
P/E
8
P/B
—
ROE
13.3%
ROCE
3.3%
Debt / equity
0
Dividend yield
2.40%
1-year return
-1.0%
52-week high
₹117.72
52-week low
₹70.46
Operating margin
31.3%
Growth
| Revenue (last 12 months) | ₹239 cr |
| Net profit (last 12 months) | ₹321 cr |
| Sales growth, 3 years (yearly) | 23.6% |
| Profit growth, 3 years (yearly) | 18.5% |
Similar companies
Shukra Pharmaceuticals Ltd. (SHUKRAPHAR) · Hikal Limited (HIKAL) · Fredun Pharmaceuticals Ltd. (FREDUN) · Dishman Carbogen Amcis Ltd. (DCAL) · Venus Remedies Limited (VENUSREM)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALEMBICLTD in NSE Scanner →